Author:
Vitale Antonio,Caggiano Valeria,Sfikakis Petros P.,Dagna Lorenzo,Lopalco Giuseppe,Ragab Gaafar,La Torre Francesco,Almaghlouth Ibrahim A.,Maggio Maria Cristina,Sota Jurgen,Tufan Abdurrahman,Hinojosa-Azaola Andrea,Iannone Florenzo,Loconte Roberta,Laskari Katerina,Direskeneli Haner,Ruscitti Piero,Morrone Maria,Mayrink Giardini Henrique A.,Panagiotopoulos Alexandros,Di Cola Ilenia,Martín-Nares Eduardo,Monti Sara,De Stefano Ludovico,Kardas Rıza Can,Duran Rahime,Campochiaro Corrado,Tomelleri Alessandro,Alabdulkareem Abdulaziz Mohammed,Gaggiano Carla,Tarsia Maria,Bartoloni Elena,Romeo Mery,Hussein Mohamed A.,Laymouna Ahmed Hatem,Parente de Brito Antonelli Isabele,Dagostin Marilia Ambiel,Fotis Lampros,Bindoli Sara,Navarini Luca,Alibaz-Oner Fatma,Sevik Gizem,Frassi Micol,Ciccia Francesco,Iacono Daniela,Crisafulli Francesca,Portincasa Piero,Jaber Nour,Kawakami-Campos Perla Ayumi,Wiesik-Szewczyk Ewa,Iagnocco Annamaria,Simonini Gabriele,Sfriso Paolo,Balistreri Alberto,Giacomelli Roberto,Conti Giovanni,Frediani Bruno,Fabiani Claudia,Cantarini Luca
Abstract
IntroductionThe effectiveness of canakinumab may change according to the different times it is used after Still’s disease onset. This study aimed to investigate whether canakinumab (CAN) shows differences in short- and long-term therapeutic outcomes, according to its use as different lines of biologic treatment.MethodsPatients included in this study were retrospectively enrolled from the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Still’s disease. Seventy-seven (51 females and 26 males) patients with Still’s disease were included in the present study. In total, 39 (50.6%) patients underwent CAN as a first-line biologic agent, and the remaining 38 (49.4%) patients were treated with CAN as a second-line biologic agent or subsequent biologic agent.ResultsNo statistically significant differences were found between patients treated with CAN as a first-line biologic agent and those previously treated with other biologic agents in terms of the frequency of complete response (p =0.62), partial response (p =0.61), treatment failure (p >0.99), and frequency of patients discontinuing CAN due to lack or loss of efficacy (p =0.2). Of all the patients, 18 (23.4%) patients experienced disease relapse during canakinumab treatment, 9 patients were treated with canakinumab as a first-line biologic agent, and nine patients were treated with a second-line or subsequent biologic agent. No differences were found in the frequency of glucocorticoid use (p =0.34), daily glucocorticoid dosage (p =0.47), or concomitant methotrexate dosage (p =0.43) at the last assessment during CAN treatment.ConclusionCanakinumab has proved to be effective in patients with Still’s disease, regardless of its line of biologic treatment.